Clin2
NCT07318584Likely a fitNot yet recruiting

Cefotetan for E. coli bloodstream infections

E Coli InfectionESBL Producing E.Coli

Part of Infections clinical trials.

This trial tests whether the antibiotic cefotetan works as well as or better than standard treatments for E. coli bloodstream infections. You may be eligible if you have a confirmed E. coli infection in your blood that started in your urinary or genital area, and you have just started antibiotics in the hospital.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
84 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have an E. coli infection in your blood that started from your urinary or genital area.
  • Your doctors have started giving you antibiotics for this infection in the hospital within the last 2 days.
  • You are not allergic to cefotetan or certain other antibiotics (like ertapenem, meropenem, or ceftriaxone).
  • You have not been in the hospital in the past 30 days.
  • You are not pregnant or breastfeeding.
  • You are not severely ill (e.g., in the ICU) or have a weak immune system from conditions like cancer, organ transplant, or recent chemotherapy.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07725848Not yet recruiting
Testing a new antibiotic for severe urinary infections in the blood

This trial tests a new antibiotic combination, cefepime/enmetazobactam, against standard therapy for people with complicated urinary tract infections that have spread to the bloodstream. It aims to see if the new drug works better and is safe.

Bologna, Italy
NCT03671967Recruiting· Phase 4
Compare two antibiotics for hard-to-treat E. coli and Klebsiella bloodstream infections

This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.

Calgary, Alberta
NCT06342115Recruiting· Phase 4
Ceftolozane/tazobactam vs meropenem for febrile neutropenia with ESBL risk

This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.

São Paulo
NCT07236944Recruiting· Phase 4
Testing pivmecillinam pills for E. coli kidney infection

This trial tests if a switch to pivmecillinam pills after IV antibiotics works as well as standard oral antibiotics for E. coli febrile urinary tract infections. It aims to simplify treatment for patients who are already stable.

Haukeland
NCT07299539Recruiting
Treatment study for enterococcus faecalis bloodstream infection

This trial looks at how well certain penicillin-type antibiotics work for treating a bloodstream infection caused by a bacterium called Enterococcus faecalis. It may help doctors know which treatment is best for patients with this infection.

Strasbourg
NCT05224401Recruiting· Phase 3
Oral antibiotic step-down for ESBL bladder infections

This Phase 3 trial tests whether switching from short-term IV antibiotics to an oral antibiotic combo is safe and effective for ESBL urine infections. It may help you avoid staying on IV antibiotics as long, if your bacteria are the right match.

Helsingborg

Hear when a new E Coli Infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.